The lowest-rated Medicare dialysis centers are operated by a supplier preparing to defend thousands of NaturaLyte and GranuFlo lawsuit claims, a new rating system finds.

A report published January 26th by ModernHealthCare.com notes the findings of a new five-star rating system instituted by the federal agency, which puts quality in Fresenius Medical Care facilities ahead of that in treatment centers operated by DaVita Kidney Care. DaVita refers to the results, which are posted to the CMS Dialysis Facility Compare website, “gratifying.”

Here’s what was recorded: Fresenius facilities accounted for more than half of the dialysis facilities nationwide that had “much below average quality,” and were given one star. 259 sites owned by the company received this low mark, with just 53 providing the highest quality, at five stars. More than 1,738 Fresenius facilities were included in the new rating system. 324 out of 1,785 operated by DaVita Kidney Care, the largest division of DaVita Healthcare Partners, were given five stars for quality, in comparison.

Overall, 565 total dialysis facilities nationwide were determined in the CMS to have “much above average quality,” based on a number of measures, including standardized ratios for transfusions, mortality, hospitalizations and also KtV values, which show whether enough waste was extracted from the patient in dialysis.

The number of dialysis patients with high calcium levels was also factored into quality determinations.

Fresenius Continues to Defend Thousands of GranuFlo Recall Lawsuits

Findings of this research may be hard-hitting for Fresenius, which is defending nearly 3,000 GranuFlo and NaturaLyte lawsuits in federal court alone. These claims, which were filed in a multidistrict litigation (MDL) in the U.S. District Court, District of Massachusetts, allege strokes, heart attacks, sudden cardiac death and other life-threatening injuries that occurred after administration of the dialysis concentrates. These individuals accuse Fresenius of failing to adequately warn about these risks prior to a GranuFlo recall issued in June 2012 by the U.S. Food and Drug Administration (FDA), who determined at this time that heart problems allegedly caused by the medications to be serious, and potentially fatal. A number of additional claims against Fresenius are also pending in a consolidated litigation underway in a state proceeding established in Middlesex County Superior Court.

Consider a GranuFlo Lawsuit

Call a GranuFlo lawyer at our Firm to learn about the claims that have already been filed against Fresenius, and whether you can file a dialysis lawsuit of your own. Contact us today at (877) 779-1414.

Published January 28, 2015 by